Vyome Holdings, Inc. — 2021 Q1 Form 10-Q Summary
Filing identity: The supplied filing is for Obalon Therapeutics, Inc. (NASDAQ: OBLN), not Vyome Holdings, Inc. It covers the three months ended March 31, 2021; financial statements are unaudited. The company described itself as a medical-device business developing and commercializing the Obalon intragastric balloon system, but had largely suspended commercial operations.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | $0 | $780,000 |
| Gross profit | $0 | $239,000; gross margin was about 31% of revenue |
| Research and development | $112,000 | $1.257 million |
| Selling, general and administrative | $4.056 million | $3.893 million |
| Operating loss | $4.168 million | $4.911 million |
| Net loss | $4.167 million; $0.44 per share | $5.261 million; $0.68 per share |
| Operating cash flow | -$4.442 million | -$4.814 million |
| Investing cash flow | $0 | -$326,000 |
| Financing cash flow | $9.509 million | $0 |
At March 31, 2021, cash and cash equivalents were $8.972 million, versus $3.905 million at year-end 2020. Current assets were $12.794 million and current liabilities $6.863 million. Total assets were $17.343 million, total liabilities $7.245 million, and stockholders’ equity $10.098 million. Accumulated deficit was $188.931 million.
Reported debt was $430,000, representing the Paycheck Protection Program loan; the filing says the prior term loan had been paid off in Q3 2020. The PPP loan bears 1% interest, had not been submitted for forgiveness as of March 31, and may become payable in full upon a change of control unless the lender agrees otherwise. The company raised $9.509 million from warrant exercises covering approximately 2.3 million shares; outstanding shares rose to 10,021,568 from 7,770,698 at December 31, 2020.
Changes versus the prior comparable period
- Revenue and cost of revenue fell to zero as the company suspended sales and wound down its retail treatment-center model.
- R&D expense declined by $1.145 million, principally reflecting reduced operations and personnel.
- SG&A increased by $163,000, primarily due to merger-related legal and accounting fees, partly offset by lower operating costs.
- Net loss narrowed by $1.094 million. Operating cash use improved by $372,000.
- Cash increased by $5.067 million during the quarter, mainly due to warrant-exercise proceeds; operating activities continued to consume cash.
Outlook, significant events and risks
- Obalon said it did not plan to reopen treatment centers, restart manufacturing, resume U.S. shipments, or resume its former international distribution arrangement. It did not expect meaningful revenue for the foreseeable future.
- Management estimated that March 31 cash would fund operations through the end of June 2022. The notes also state that existing cash was expected to cover forecast expenses, capital spending and debt service for at least 12 months from issuance of the statements. These estimates depend on the company’s limited operating plans and available funding.
- On January 19, 2021, Obalon agreed to merge with ReShape Lifesciences. Subject to approvals and other closing conditions, ReShape stockholders would own 51% of the combined company after the transaction; Obalon was expected to be renamed ReShape Lifesciences, Inc. and ReShape’s directors and executives would lead it. The merger was not yet completed as of the filing.
- The company had reduced staffing to two full-time employees. It had stopped pursuing third-party reimbursement and was focused on the merger. Failure to complete the merger or secure adequate funding could materially affect its business and financial condition.
- COVID-19-related restrictions and the deferral of elective procedures had adversely affected operations. The filing cautions that additional capital may not be available on acceptable terms, or at all.
- The $3.15 million settlement of a prior securities class action was paid by insurance carriers; the court approved the settlement and dismissed the case on April 22, 2021. A landlord dispute resulted in payment of a $469,000 writ of attachment; the company said it was current on rent.
- As of April 29, 2021, eight lawsuits had been filed by alleged stockholders challenging merger-related disclosures and seeking, among other relief, to block the transaction. Obalon disputed the allegations and said it voluntarily supplemented its proxy materials.
Important facts for investors to verify
- Confirm the filing’s issuer: this document reports Obalon Therapeutics, Inc., despite the request identifying Vyome Holdings, Inc.
- Check the merger’s final status, shareholder and Nasdaq approvals, closing conditions, and resulting ownership and dilution.
- Verify the company’s cash runway against actual spending, merger costs, debt service and any subsequent financing.
- Confirm the PPP loan’s forgiveness or repayment status and whether a change of control triggers repayment.
- Review the status and potential costs of the merger-related stockholder lawsuits and any further disclosure or settlement developments.
- Assess whether any credible path to operations or revenue exists given the stated suspension of commercial activity and lack of expected meaningful revenue.